TNYA Stock Analysis: Buy, Sell, or Hold?
TNYA - Tenaya Therapeutics, Inc. Common Stock
$0.73
0.02 (2.68%)
▲
5d:
+1.5%
30d:
-7.23%
90d:
-9.1%
BUY
MODERATE Confidence
Analysis Updated: Jun 18, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When TNYA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TNYA shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: TNYA shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: TNYA is currently trading at $0.73, which is considered slightly low relative to its 30-day fair value range of $0.71 to $0.88. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.8) compared to its historical average (10.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TNYA is in a strong uptrend. Immediate support is located at $0.68, while resistance sits at $0.95.
Market Sentiment: TNYA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $4.00 (+447.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TNYA is in a strong uptrend. Immediate support is located at $0.68, while resistance sits at $0.95.
Market Sentiment: TNYA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $4.00 (+447.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.71 -
$0.88
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 447.5% below Wall St target ($4.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$0.71 -
$0.88
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.68
Resistance Level
$0.95
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.76
Wall Street Target
$4.00
(+447.5%)
PE vs Historical
-1.8 vs 10.3
CHEAP
Share & Embed Analysis
Last updated: June 18, 2026 10:34 PM ET
Data refreshes hourly during market hours. Next update: 11:34 PM
Data refreshes hourly during market hours. Next update: 11:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TNYA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Group Gp Lp Column III
SELL
3511826 shares
2026-02-25
Group Gp Lp Column III
SELL
658440 shares
2026-02-24
Faraz Ali
SELL
14862 shares
2026-02-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 68 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 55 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$102 | 56 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 67 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$256 | 62 BUY |
